Kepos Capital’s Immunome IMNM Stock Holding History

Kepos Capital’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-66,666	Closed	-$645K	–	433
2020 Q4	$645K	Buy	+66,666	New	+$778K	0.06%	224

Other funds holding IMNM

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

PCM

Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BIM

Baldwin Investment Management West Conshohocken, Pennsylvania $856M AUM 9.05% 1-Year Est. Return

Kepos Capital's IMNM Position: Q1 2021 in Review

Kepos Capital sold out of Immunome (IMNM) in Q1 2021, closing a stake of 66,666 shares — an estimated $645K sold.

Kepos Capital first reported a position in IMNM in Q4 2020 and held it in 1 quarter. The position peaked at $645K in Q4 2020. 31 funds tracked by Wall St. Rank hold IMNM as of Q1 2021.

Kepos Capital reported no remaining Immunome position as of Q1 2021 after selling out during the quarter.
Kepos Capital sold 66,666 Immunome shares in Q1 2021, an estimated $645K.
Kepos Capital first reported a position in Immunome in Q4 2020 and held it in 1 quarter.
Kepos Capital's Immunome position peaked at $645K in Q4 2020.
31 funds tracked by Wall St. Rank held Immunome as of Q1 2021.

Based on Kepos Capital's 13F filing for Q1 2021, filed 13 May 2021.